首页> 美国卫生研究院文献>PLoS Clinical Trials >Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer

【2h】

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer

机译：HER2，阳性转移性乳腺癌中HER2，p95HER2和HER3表达的相关性以及拉帕替尼联合卡培他滨的治疗结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundLapatinib plus capecitabine is an effective treatment option for trastuzumab-refractory HER2-positive metastatic breast cancer. We have investigated the correlation between quantitative measures of HER2, p95HER2, and HER3 and treatment outcomes using lapatinib and capecitabine.

机译：背景拉帕替尼加卡培他滨是曲妥珠单抗难治性HER2阳性转移性乳腺癌的有效治疗选择。我们研究了HER2，p95HER2和HER3定量指标与使用拉帕替尼和卡培他滨的治疗结果之间的相关性。

著录项

期刊名称 PLoS Clinical Trials
作者
Sae-Won Han; Yongjun Cha; Agnes Paquet; Weidong Huang; Jodi Weidler; Yolanda Lie; Thomas Sherwood; Michael Bates; Mojgan Haddad; In Hae Park; Do-Youn Oh; Keun Seok Lee; Seock-Ah Im; Yung-Jue Bang; Jungsil Ro; Tae-You Kim;
展开▼
作者单位

展开▼
年(卷),期 2009(7),7
年度 2009
页码 e39943
总页数 7
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab [J] . Nishimura Reiki, Toh Uhi, Tanaka Maki, Oncology: International Journal of Cancer Research and Treatment . 2017 ,第1期

机译：HER2相关生物标志物（HER2，P95HER2，HER3，PTEN和PIK3CA）的作用在Lapatinib Plus Capecitabine在HER2阳性晚期乳腺癌难治性对Trastuzumab的疗效
2. HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer [J] . LiptonA., GoodmanL., LeitzelK., Breast cancer research and treatment. . 2013 ,第1期

机译：HER3，p95HER2和HER2蛋白表达水平定义了HER2阳性转移性乳腺癌的多种亚型
3. Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases |[ndash]| the UK experience [J] . S Sutherland, S Ashley, D Miles, British Journal of Cancer . 2010 ,第6期

机译：拉帕替尼和卡培他滨在拉帕替尼扩大治疗方案中治疗HER2阳性转移性乳腺癌，包括脑转移的疗效| [ndash] |英国的经验
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Predictive value of quantitative HER2 HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab [O] . Renata Duchnowska, Jeff Sperinde, Bogumiła Czartoryska-Arłukowicz, 2017

机译：在曲妥珠单抗治疗后接受拉帕替尼治疗的HER2阳性晚期乳腺癌患者中定量HER2HER3和p95HER2水平的预测价值
7. Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer. [O] . Sae-Won Han, Yongjun Cha, Agnes Paquet, 2012

机译：拉帕替尼联合卡培他滨治疗HER2阳性转移性乳腺癌HER2，p95HER2和HER3表达与治疗结果的相关性。

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer

摘要

著录项

相似文献

相关主题

期刊订阅